Clinical Trial Update: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) [Phase 1]

View source ↗

Summary

Phase 1 trial update describes a combination of Motixafortide and Natalizumab to mobilize CD34+ hematopoietic stem cells for gene therapies in sickle cell disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Motixafortide (motixafortide)
• Natalizumab (natalizumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Sickle Cell Disease | Phase 1 | Status: COMPLETED